Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire's Fosrenol Gets FDA Nod, Will Be Available By Year-End

This article was originally published in The Pink Sheet Daily

Executive Summary

Fosrenol will compete directly with Genzyme's Renagel; both products are non-calcium, non-aluminum containing phosphate binders. Shire estimates that less than one-third of the 800,000 ESRD patients with elevated phosphate levels are able to control their phosphorus levels with existing medications.

You may also be interested in...



Genzyme: Next-Generation Sevelamer Bound For Clinic Next Year

Enzyme-replacement sales strong as firm builds on renal franchise.

Genzyme: Next-Generation Sevelamer Bound For Clinic Next Year

Enzyme-replacement sales strong as firm builds on renal franchise.

Fosrenol Approved In Higher Dose Formulation

FDA has approved a higher dose formulation for the end-stage renal disease agent Fosrenol (lanthanum), Shire announced Nov. 28

Related Content

Topics

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel